Mylan: Working Together to Provide 7 Billion People Access to High Quality Medicine

Published Online: Wednesday, August 29, 2012
Follow Pharmacy_Times:


Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in approximately 150 countries and territories. The company maintains a broad, high quality product portfolio, which is regularly bolstered by an innovative and robust pipeline. With a workforce of more than 18,000, Mylan has attained leading positions in key international markets through its wide array of dosage forms and delivery systems, significant manufacturing capacity, global commercial scale, and a committed focus on quality and customer service. The company ranks among the top 5 generics companies in several international markets and is the largest US-based generics manufacturer in the world.

A Commitment to Quality
The bulk of Mylan’s product portfolio, which consists of more than 1100 individual products, includes high quality, affordable generic medications sold throughout the world. Mylan innovates every day to be among the first to bring these new medications to market. By introducing groundbreaking technologies and difficult to manufacture and formulate pharmaceuticals, the company seamlessly and efficiently delivers high quality products at competitive prices. Additionally, the distinctive Mylan blue bottle packaging allows its products to stand out from all the others.

Supply and Support
With a global manufacturing capacity of 45 billion doses, Mylan customers can count on a continuous supply of high quality products. Furthermore, Mylan Laboratories Limited, a subsidiary of Mylan, produces active pharmaceutical ingredients (API) in a wide range of categories and is the world’s largest producer of API used to make antiretroviral (ARV) therapies for the treatment of HIV/AIDS. The company’s dedication to quality, supply and customer service makes Mylan a company that customers can truly rely on.

Innovative Solutions
Mylan operates a fully integrated specialty pharmaceutical business, which is focused on the development, manufacturing and marketing of branded drug products. Mylan Specialty, the company’s fully integrated specialty pharmaceutical business, is focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, life-threatening allergic reactions and psychiatric disorders.

An Ever-Expanding Portfolio
Ranging from generic to branded, oral to injectable, the company’s offerings lead the way in more than 20 disease categories, such as CNS and CV, and provide solutions for millions affected by diabetes and HIV. Discover how Mylan’s portfolio of quality products delivers unique opportunities for partnership and support.

For more information, visit www.mylan.com.



Related Articles
Mylan Inc. announced the U.S. launch of its Methocarbamol Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose vials.
Patients with bipolar disorder and other mental illnesses are more likely to be tested for human immunodeficiency virus.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Mylan Inc. announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg.
Latest Issues
$auto_registration$